Can you specify the lipitor reduction amount?

Patent Expiration and Lipitor Price Reduction Effects

Lipitor, a cholesterol-lowering medication, was first approved in the United States in 1997 [1]. Under patent protection, Pfizer held exclusive rights to sell the medication, resulting in higher prices.

Who Challenges the Patent?

As Lipitor's patent expiration timeline approaches, generic manufacturers begin researching and developing their versions of the drug. Companies like Apotex, Mylan, and Teva Pharmaceutical Industries challenge Lipitor's patent, seeking to enter the market with their versions at lower prices [2][3].

Timeline of Patent Expiration

Lipitor's patent expires in 2019 in the United States, allowing generic versions of the medication to enter the market [4]. After the patent expires, generic versions of the medication become available to consumers, reducing the overall cost of the medication. According to DrugPatentWatch.com, Lipitor's price reduction was significant following the patent expiration [5].

How Much Did Lipitor's Price Reduce?

Following Lipitor's patent expiration, the price of the medication decreased significantly, with some reports indicating a price drop of over 90% [5]. This drastic reduction made Lipitor more affordable to consumers, improving accessibility to healthcare services.

When Is the Patent Expiration Relevant?

Generic manufacturers typically enter the market within months of the patent expiration, providing consumers with lower-cost alternatives. After the patent expires, Lipitor's price reduction allowed for greater competition in the market.

However, some reports indicate that prices for Lipitor may fluctuate over time. According to the U.S. Department of Health and Human Services, generic drugs can see price spikes due to market factors such as production costs or market demand [6].

Sources:

[1] FDA website: 'Lipitor (Atorvastatin Calcium)'
[2] Teva Pharmaceutical Industries Ltd. - News Release: 'Teva to Launch Atorvastatin Calcium Tablets'
[3] Mylan N.V. - News Release: 'Mylan Announces Launch of Atorvastatin Calcium Tablets'
[4] FDA website: 'Patents and Exclusivity'
[5] DrugPatentWatch.com - 'Lipitor (Atorvastatin Calcium): Patent Expiration'
[6] HHS.gov - 'Price Spike Data from Manufacturers of Generic Medications'